Analysis of gene expression during the first 10 weeks following PEG-interferon-alfa2B/ribavirin treatment of a group of hepatitis C raments

被引：0
|
作者：
Taylor, Milton W.
Tsukahara, Takurna
Kwo, Paul
机构：
[1] Indiana Univ, Bloomington, IN USA
[2] Indiana Univ, Sch Med, Indianapolis, IN 46204 USA
来源：
HEPATOLOGY | 2007年 / 46卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
283
引用
收藏
页码：365A / 365A
页数：1
相关论文
共 50 条
  • [31] A randomized, controlled, open label study of 16 weeks' treatment with Peg-interferon alfa-2a and ribavirin in patients with chronic hepatitis C genotype 2
    Yu, M.
    Dai, C.
    Chang, W.
    Lee, L.
    Hsieh, M.
    Lin, Z.
    Hsieh, M.
    Hou, N.
    Wang, L.
    Chuang, W.
    Chen, S.
    LIVER INTERNATIONAL, 2006, 26 : 75 - 75
  • [32] Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C
    Kim, WR
    Poterucha, JJ
    Gross, JB
    HEPATOLOGY, 2000, 31 (03) : 807 - 807
  • [33] Treatment with combination peginterferon alfa-2b and ribavirin of recurrent hepatitis C in liver transplant recipients nonresponsive to interferon alfa-2b and ribavirin
    Samanta, A
    Mandalapu, A
    Fisher, A
    Wilson, D
    de la Torre, A
    Klein, KM
    Koneru, B
    GASTROENTEROLOGY, 2005, 128 (04) : A455 - A456
  • [34] PEG-interferon-alpha-2b and ribavirin treatment in children and adolescents with chronic hepatitis C
    Wirth, S
    Ballauff, A
    Kullmer, U
    Lang, T
    Wintermeyer, P
    Gerner, P
    HEPATOLOGY, 2004, 40 (04) : 344A - 344A
  • [35] Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin
    Antonini, M. G.
    Babudieri, S.
    Maida, I.
    Baiguera, C.
    Zanini, B.
    Fenu, L.
    Dettori, G.
    Manno, D.
    Mura, M. S.
    Carosi, G.
    Puoti, M.
    INFECTION, 2008, 36 (03) : 250 - 255
  • [36] Incidence of Neutropenia and Infections During Combination Treatment of Chronic Hepatitis C with Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin
    M. G. Antonini
    S. Babudieri
    I. Maida
    C. Baiguera
    B. Zanini
    L. Fenu
    G. Dettori
    D. Manno
    M. S. Mura
    G. Carosi
    M. Puoti
    Infection, 2008, 36 : 250 - 255
  • [37] The Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.
    Fontaine, H
    Pol, S
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1999, 23 (04): : 541 - 544
  • [38] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    Manns, MP
    McHutchison, JG
    Gordon, SC
    Rustgi, VK
    Shiffman, M
    Reindollar, R
    Goodman, ZD
    Koury, K
    Ling, MH
    Albrecht, JK
    LANCET, 2001, 358 (9286): : 958 - 965
  • [39] Influence of predictor variables on side effects of the treatment with PEG Interferon Alfa 2a plus ribavirin in chronic hepatitis C
    Sargsyants, N.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : S69 - S69
  • [40] Danazol in the treatment of thrombocytopenia associated with the use of peg-interferon alfa 2a and Ribavirin in patients with chronic hepatitis C
    Gomez-Galicia, Diana
    Cabrera-Alvarez, Guillermo
    Rodriguez-Fragoso, Lourdes
    Reyes-Esparza, Jorge
    FASEB JOURNAL, 2010, 24
12345